Bronchoreversibility and Radiologic Morphology of Emphysema
NCT ID: NCT02008162
Last Updated: 2013-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bronchodilators
Patients with severe heterogeneous emphysema selected as potential candidtes for lung volume reduction surgery.
Bronchodilators employed for the study include albuterol 200µg and tiotropium bromide 18 µg administered by puffs following a first spirometry and plethysmography performed after a washout period of 48h from all bronchodilators and subsequently repeated within 30 min after bronchodilators administration.
Bronchodilators
Administration of both albuterol and tiotropium bromide after a 48h period of washout from all bronchodilators, followed by spirometry and plethysmography
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bronchodilators
Administration of both albuterol and tiotropium bromide after a 48h period of washout from all bronchodilators, followed by spirometry and plethysmography
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* GOLD COPD class III-IV
* No other significant pulmonary comorbidity
* Quit smoking since at least 4 months
20 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Rome Tor Vergata
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eugenio Pompeo
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eugenio Pompeo, MD
Role: PRINCIPAL_INVESTIGATOR
Tor Vergata University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondazione Policlinico Tor Vergata
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Eugenio Pompeo, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BREPTV-108.7
Identifier Type: -
Identifier Source: org_study_id